Proteasome Inhibitor

Overview

Proteasomes are small, barrel shaped structures that are found in all cells. They play an important role in maintaining a healthy cell environment by removing ineffective proteins. This is important because cancerous plasma cells produce large amounts of ineffective proteins.

A proteasome inhibitor temporarily stops (or inhibits) the proteasomes from doing their job. This allows the ineffective proteins to build up inside of the cancer cell until it ultimately destroys itself.

There are several proteasome inhibitors that are approved for use in multiple myeloma. This classification of drug is currently given in one of three ways - as an IV infusion, as a shot in the abdominal area or as an oral pill.

Explore Tags

Myeloma Treatments

The following is a listing of myeloma treatments associated with this tag.

Untreated / Newly Diagnosed Multiple Myeloma

The following is a listing of treatments in development for patients with multiple myeloma who have been newly diagnosed or have not yet received treatment.

Bortezomib Velcade®
View Treatment
Carfilzomib Kyprolis®
View Treatment
Ixazomib Ninlaro®
View Treatment
Early Relapse Multiple Myeloma

The following is a listing of treatments in development for patients with multiple myeloma who have received one to two prior lines of therapy.

Bortezomib Velcade®
View Treatment
Carfilzomib Kyprolis®
View Treatment
Ixazomib Ninlaro®
View Treatment
Late Relapse Multiple Myeloma

The following is a listing of treatments in development for patients with multiple myeloma who have received three or more prior lines of therapy.

Bortezomib Velcade®
View Treatment
Carfilzomib Kyprolis®
View Treatment
Ixazomib Ninlaro®
View Treatment
Smoldering Myeloma

The following is a listing of treatments in development for patients with Smoldering Myeloma.

Bortezomib Velcade®
View Treatment
Carfilzomib Kyprolis®
View Treatment
Ixazomib Ninlaro®
View Treatment
Myeloma Clinical Trials

The following is a listing of myeloma clinical trials associated with this tag.

All Clinical Trials

View all active clinical trials around the US.

Verified
Daratumumab, Carfilzomib, Pomalidomide, Dexamethasone In MM
DARATUMUMAB COMBINATION THERAPY
View Trial
Verified
Phase 3 Clinical Trial Comparing a Study Medication Alone Versus Pomalidomide, Bortezomib, Dexamethasone or Carfilzomib and Dexamethasone in Patients with Re...
MAJESTEC-9
View Trial
Verified
Phase 3 Clinical Trial Comparing the Safety and Effectiveness of Elranatamab Versus Commonly Used Combination Regimens in Participants with Relapsed/Refracto...
MAGNETISMM-32
View Trial

SparkCures Verified Accurate, up-to-date information. Learn more

A Phase II Study of CyBorD (Cyclophosphamide, Bortezomib, Dexamethasone) Plus Daratumumab for Patients With...
CYBORD PLUS DARATUMUMAB
View Trial
A Phase III Randomized Trial for Newly Diagnosed Multiple Myeloma (NDMM) Patients Considered Frail or in a ...
TRIPLET INDUCTION + 1 OR 2-DRUG MAINTENANCE
View Trial
A Protocol to Assess the Safety, Efficacy, and Pharmacokinetics of Continuous Subcutaneous Administration o...
STAR-LLD
View Trial
A Randomized Phase 2 Study of Daratumumab-Selinexor-Velcade-Dexamethasone (Dara-SVD) for High-Risk Newly Di...
DARA-SVD VS. DARA-RVD
View Trial
A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments f...
LINVOSELTAMAB
View Trial
Bortezomib, Isatuximab, Cyclophosphamide and Dexamethasone Induction in Transplant-Eligible Multiple Myelom...
VICD
View Trial
Carfilzomib Based Chemotherapy Mobilization for Autologous Stem Cell Transplants in Multiple Myeloma (CarMob)
CARMOB
View Trial
Combination Treatment Therapy Approaches for the Treatment of High-Risk Multiple Myeloma, REACH Trial
REACH
View Trial
Ixazomib + Pomalidomide + Dexamethasone In Multiple Myeloma
IXAZOMIB COMBINATION THERAPY
View Trial
Phase I/II Trial of Mezigdomide Plus Ixazomib and Dexamethasone for Relapsed and Refractory Multiple Myeloma
MEZIGDOMIDE PLUS IXAZOMIB
View Trial
Pilot Study of Daratumumab in Combination With Bortezomib, Cyclophosphamide, and Dexamethasone (Dara-CyBorD...
DARATUMUMAB FOR PATIENTS WITH RENAL FAILURE
View Trial
Bortezomib and Pembrolizumab With or Without Pelareorep for the Treatment of Relapsed or Refractory Multipl...
AMBUSH
View Trial
Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in ...
TAPUR
View Trial
Untreated / Newly Diagnosed Multiple Myeloma

The following is a listing of clinical trials for patients with multiple myeloma who have been newly diagnosed or have not yet received treatment.

A Phase II Study of CyBorD (Cyclophosphamide, Bortezomib, Dexamethasone) Plus Daratumumab for Patients With...
CYBORD PLUS DARATUMUMAB
View Trial
A Phase III Randomized Trial for Newly Diagnosed Multiple Myeloma (NDMM) Patients Considered Frail or in a ...
TRIPLET INDUCTION + 1 OR 2-DRUG MAINTENANCE
View Trial
A Randomized Phase 2 Study of Daratumumab-Selinexor-Velcade-Dexamethasone (Dara-SVD) for High-Risk Newly Di...
DARA-SVD VS. DARA-RVD
View Trial
Bortezomib, Isatuximab, Cyclophosphamide and Dexamethasone Induction in Transplant-Eligible Multiple Myelom...
VICD
View Trial
Carfilzomib Based Chemotherapy Mobilization for Autologous Stem Cell Transplants in Multiple Myeloma (CarMob)
CARMOB
View Trial
Combination Treatment Therapy Approaches for the Treatment of High-Risk Multiple Myeloma, REACH Trial
REACH
View Trial
Early Relapse Multiple Myeloma

The following is a listing of clinical trials for patients with multiple myeloma who have received one to two prior lines of therapy.

Verified
Daratumumab, Carfilzomib, Pomalidomide, Dexamethasone In MM
DARATUMUMAB COMBINATION THERAPY
View Trial
Verified
Phase 3 Clinical Trial Comparing the Safety and Effectiveness of Elranatamab Versus Commonly Used Combination Regimens in Participants with Relapsed/Refracto...
MAGNETISMM-32
View Trial

SparkCures Verified Accurate, up-to-date information. Learn more

A Protocol to Assess the Safety, Efficacy, and Pharmacokinetics of Continuous Subcutaneous Administration o...
STAR-LLD
View Trial
A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments f...
LINVOSELTAMAB
View Trial
Carfilzomib Based Chemotherapy Mobilization for Autologous Stem Cell Transplants in Multiple Myeloma (CarMob)
CARMOB
View Trial
Ixazomib + Pomalidomide + Dexamethasone In Multiple Myeloma
IXAZOMIB COMBINATION THERAPY
View Trial
Phase I/II Trial of Mezigdomide Plus Ixazomib and Dexamethasone for Relapsed and Refractory Multiple Myeloma
MEZIGDOMIDE PLUS IXAZOMIB
View Trial
Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in ...
TAPUR
View Trial
Late Relapse Multiple Myeloma

The following is a listing of clinical trials for patients with multiple myeloma who have received three or more prior lines of therapy.

Verified
Daratumumab, Carfilzomib, Pomalidomide, Dexamethasone In MM
DARATUMUMAB COMBINATION THERAPY
View Trial
Verified
Phase 3 Clinical Trial Comparing the Safety and Effectiveness of Elranatamab Versus Commonly Used Combination Regimens in Participants with Relapsed/Refracto...
MAGNETISMM-32
View Trial

SparkCures Verified Accurate, up-to-date information. Learn more

A Protocol to Assess the Safety, Efficacy, and Pharmacokinetics of Continuous Subcutaneous Administration o...
STAR-LLD
View Trial
A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments f...
LINVOSELTAMAB
View Trial
Ixazomib + Pomalidomide + Dexamethasone In Multiple Myeloma
IXAZOMIB COMBINATION THERAPY
View Trial
Phase I/II Trial of Mezigdomide Plus Ixazomib and Dexamethasone for Relapsed and Refractory Multiple Myeloma
MEZIGDOMIDE PLUS IXAZOMIB
View Trial
Bortezomib and Pembrolizumab With or Without Pelareorep for the Treatment of Relapsed or Refractory Multipl...
AMBUSH
View Trial
Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in ...
TAPUR
View Trial
Smoldering Myeloma
Monoclonal Gammopathy of Undetermined Significance (MGUS)

Resources